genedrive plc Annual Report 2017 genedrive plc Annual Report Decentralising molecular diagnostics 17 genedrive plc Annual Report 2017 Page Title at start: Content Section at start: genedrive plc Annual Report 2017 genedrive plc is focused on decentralising molecular diagnostics.Strategic Report Highlights 1 Our Focus 2 Chairman's Statement 4 Chief Executive's Review 6 Market Opportunity 8 Financial Review 12 Key Performance Indicators 13 Principal Risks And Uncertainties 15 Governance Board of Directors 16 Directors' Report 18 Directors' Remuneration Report 21 Corporate Governance Report 25 Financial Statements Independent Auditor's Report (Group) genedrive plc Annual Report 2017 3 LOW COST PORTABLE Decentralised testing supported by mains power or UPS battery pack.Affordable platform facilitates testing in low throughput settings.How Genedrive® works Genedrive® utilises proprietary technology to rapidly amplify and detect target nucleic acid sequences without the requirement for Dear Shareholder I am pleased to report that 2016/17 has seen us make further progress on our journey to refocus the Company on the highly attractive opportunities which the Genedrive® diagnostics platform offers in the rapidly growing market for decentralised, near patient diagnostic tests.Key Achievements A major focus for the year was the development as stated in the trading statement of 13 July 2017, no additional short term revenues were expected from MTB/RIF in India.However, the TB market is large and there is significant potential for Genedrive®.Away from our core human healthcare focus, we enjoyed success with funded field trials of Genedrive® for white spot disease detection in farmed shrimp David Budd Chief Executive Officer We continue to make strong progress with a disciplined approach to executing our strategy.Our Performance Revenue for the period was £5.8m, up 13.7% from the £5.1m on the prior period.this year over year growth in revenue was driven by the Diagnostics division that saw revenue growth of 36.8% to £2.6 as direct acting antiviral use increases in the future, we anticipate an increased demand for diagnostics in even smaller, point of need facilities.To support future positioning in this user segment, the Company has secured a £0.6m conditional offer of development funding from Innovate UK.When confirmed the grant will be used to further our Centrifuge however, post year end an additional funding award was made to support the continuation of the project and an award was made to support ongoing validation work.This additional funding is expected to generate approximately $1.4m in development and commercial income of $0.5m for the financial year to 30 June 2018.Services Operations As previously stated, we have been seeking strategic alternatives for genedrive plc Annual Report 2017 8 Prevalence of HCV in Top 20 countries (millions) China 29.8 India 18.2 Egypt 11.8 Pakistan 9.4 Indonesia 9.4 Russia 5.8 USA 5.4 D.R.Congo 4 Nigeria 3.3 Japan 3.1 Cameroon 2.8 Brazil 2.6 Uganda 2.2 Ukraine 1.9 Philippines 1.9 genedrive plc Annual Report 2017 10 MARKET OPPORTUNITY Clinical Genedrive ® tuberculosis test is designed as an affordable, rapid PCR based test for the detection of MTB and rifampicin (Rif) resistance.Target Market The TB market is large and well defined the programme represents external validation for our development capability as well as significant funding for the enhancement and development of the Genedrive® unit.• Revenues of £2.2m (2016: £1.7m) • Units and assays delivered for fields trials • Post year end the Company announced it had entered the next stage of the programme • The Company expects around the terms of the bond were amended in the year to 30 June 2016 but had an effective date for accounting period to 30 June 2017.The total charge comprised £0.1m related to foreign exchange losses and £0.1m of fair value movements.The fair value movements include both the IFRS financing charge for the year and a fair value gain on the increase in share capital of £6.0m is directly from the shares issue in July 2016.Offsetting this increase was the consolidated loss for the year £6.4m (2016: £5.9m loss).Matthew Fowler Chief Financial Officer Growth in the Diagnostics division underpinning the performance for the year.Group Revenue Significant growth from Genedrive® Development income Results After Tax Loss before tax, interest, finance costs and impairment of intangible assets of £4.9m Cash Reserves Cash reserves of £5.1m following £6.0m Placing in July 2016 £4.5m 2015 £5.0m 2016 £5.8m 2017 £(4.0)m The Group's services to clients relate to projects which are also subject to development risk.The Board regularly monitors the client profile and seeks to broaden the client base where possible.Further information on significant clients is detailed in note 2 the financial statements.Financing Risk In the forthcoming period, the Board maintains close dialogue with the Group's advisers The Group seeks to mitigate this risk by operating a diversified business model across various technologies and territories.Approved by the Board and signed on its behalf Dr Ian Gilham Chairman 17 October 2017 Page Title at start: Content Section at start: Principal Risks And Uncertainties genedrive plc Annual Report 2017 16 BOARD OF DIRECTORS Ian Gilham Director, Research Services Catherine is a co founder of Epistem and prior to starting Epistem she worked for ten years with Prof. Chris Potten at the Paterson Institute.Whilst at the Paterson Institute she developed many pre clinical assays.This knowledge is at the core of the Epistem Contract Research Roger joined the Board as a Non Executive Director on 1 July 2007.Trained as a biochemist, Roger has 40 years experience in the healthcare and biotechnology sector, particularly in the areas of strategic planning and business development.International business management with ICI Plc and AstraZeneca Plc included living and working in the United States and Germany, The Company has one class of ordinary share which carries the right to one vote at General Meetings of the Company.The nature of the Directors' Holdings is disclosed on page 24.No person has any special rights of control over the Company's share capital and all issued shares are fully paid.genedrive plc applies employment policies which are believed to be fair and equitable and which ensure entry into and progression within the Company determined solely by personal ability and competency.DIRECTORS' REPORT For the year ended 30 June 2017 Page Title at start: Content Section at start: Directors' Report Financial Statements Governance Strategic Report genedrive plc Annual Report 2017 19 Board of Directors Under company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Group and Company and of the profit or loss of the Group and Company for that period.